VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Monday. The brokerage issued a sell rating on the stock.

VNRX has been the topic of a number of other reports. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research note on Tuesday, December 10th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Trading Up 2.2 %

VNRX stock opened at $0.63 on Monday. The firm has a 50 day moving average of $0.66 and a 200-day moving average of $0.66. The firm has a market capitalization of $58.27 million, a P/E ratio of -1.75 and a beta of 1.17. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23.

Insider Transactions at VolitionRx

In related news, Director Guy Archibald Innes acquired 174,764 shares of the stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the acquisition, the director now directly owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This represents a 39.51 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cameron John Reynolds acquired 139,811 shares of the business’s stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the completion of the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 358,266 shares of company stock worth $204,212. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC raised its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.